The National Cancer Center (NCC), led by President Yang Han-gwang, jointly announced the revised 2026 hepatocellular carcinoma (HCC) clinical guidelines with th ...
Hepatocellular carcinoma (HCC) poses a substantial health burden globally, with liver cancer being the fourth most common cause of cancer-related mortality worldwide. In China, where the incidence of ...
End-of-life (EOL) outcomes and healthcare utilization for patients with hepatocellular carcinoma (HCC) who received immune checkpoint inhibition (ICI). This is an ASCO Meeting Abstract from the 2025 ...
A risk stratification algorithm may be able to predict which patients with advanced chronic liver disease are at risk of developing hepatocellular carcinoma (HCC), according to a large-scale ...
A graphical overview of the study evaluating the clinical utility of large language models (LLMs) for hepatocellular carcinoma treatment. The study analyzed 13,614 patients to compare real-world ...
A real-world study of nab-paclitaxel-based chemotherapy with or without PD-1/PD-L1 blockade in second-line treatment of advanced biliary tract cancer. International phase II randomized ...
Hepatocellular carcinoma (HCC) is a primary malignancy of the liver and one of the leading causes of cancer-related deaths worldwide. Early detection and accurate diagnosis are crucial for effective ...
Tempest Therapeutics, Inc. announced that the FDA has granted Fast Track Designation to amezalpat (TPST-1120), an oral small molecule designed to treat hepatocellular carcinoma (HCC), recognizing its ...
Early detection of hepatocellular carcinoma (HCC) is crucial for improving patient outcomes and offers the best chance for curative treatment, making HCC screening a vital strategy for high-risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results